RxDoctor Payments Data

Aminah Jatoi, MD

Medical Oncology · Rochester, MNNPI 1437136553

Payments from drug & device makers

$216,142in general payments, 2019–2025

Across 11 payments — averaging $19,649 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$180K
  • Pfizer$33K
  • Novartis$3K

What the payments were for

  • Consulting fees$13,11836%
  • Speaking & faculty fees$22,05061%
  • Travel & lodging$7902%
  • Food & beverage$1841%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$180,000
Pfizer7$33,104
Novartis1$3,038

How this compares

$216,142 in reported general payments places this provider in the 50th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$525,720
Medicare patients
151
Services billed
16,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prochlorperazine Maleate23$238
Ondansetron Hcl17$209
Olanzapine20$177
Dexamethasone24$122

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →